Abb Vie Inc.
USPTO PatentsView assignee record - 604 granted patents across 53 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Abb ranks #759 of 49,997 tracked US assignees by granted-patent volume, with 604 patents across 53 technology areas.
- #759
- of 49,997 US assignees by volume
- Top 2%
- by Innovation Score (63.2/100)
- 17.7
- avg claims per patent
- -73%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R759 · US Corporation #759 · 604 grants
GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-WIDE · INNOV-STRONG · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL
- GRANTS-MID 604 grants
- TOP-DECILE #759/49,997
- PHOTO-FINISH SAS Institute
- CPC-WIDE A61P · 53 areas
- INNOV-STRONG 63.2/100
- CLAIMS-RICH 17.7 claims/avg
- TYPE-USCORP US Corporation
- VEL-DROP -73% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: SAS Institute, Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Abb’s 63.2 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Abb
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Nederlandse… · near
Nederlandse… · near
63 score
- Palo Alto Research… · near
Palo Alto Research… · near
63 score
- Abb Vie · this assignee
Abb Vie · this assignee
63 score
- Siemens Healthcare… · near
Siemens Healthcare… · near
63 score
- Fresenius Medical… · near
Fresenius Medical… · near
63 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Abb's Innovation Score is 63.2/100 (top 2% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Abb?
Each dot is one of Abb’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Abb’s own 17.7 claims/patent is ABOVE the 16.1 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
How Abb's grant cadence moved
Between 2020–2024, Abb Vie Inc. received 128 grants versus 468 in 2015–2019 (-73% equal-window velocity, below median growth). Across complete PatentsView years, output peaked in 2015 at 150 grants and bottomed in 2021 at 18. Lead class A61P accounts for 64.7% of the portfolio across 53 subclasses. Volume neighbours: Essilor International (#755) and Ethicon Endo-Surgery, Inc. (#763).
Abb's three-year grant acceleration
From 2019–2021 to 2022–2024, Abb Vie Inc. moved from 93 to 76 grants (0.82x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #1,782. See the growth leaderboard.
Who files at Abb's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Essilor Internati…
Essilor International
606 patents
- Sysmex
Sysmex Corporation
606 patents
- Carl Zeiss Micros…
Carl Zeiss Microscopy GmbH
605 patents
- Parker-hannifin
Parker-Hannifin Corporation
605 patents
- SAS Institute
SAS Institute, Inc.
604 patents
- Abb Vie ◀
Abb Vie Inc.
604 patents
- DIC
DIC Corporation
602 patents
- Maxlinear
MaxLinear, Inc.
602 patents
- Ethicon Endo-surg…
Ethicon Endo-Surgery, Inc.
601 patents
What this shows Abb holds 604 patents at rank #759, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Abb
By rank, the assignees closest to #759 in granted patent volume.
- Essilor International #755 · 606 patents
- Sysmex Corporation #756 · 606 patents
- Carl Zeiss Microscopy GmbH #757 · 605 patents
- Parker-Hannifin Corporation #758 · 605 patents
- SAS Institute, Inc. #760 · 604 patents
- DIC Corporation #761 · 602 patents
- MaxLinear, Inc. #762 · 602 patents
- Ethicon Endo-Surgery, Inc. #763 · 601 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Abb's primary technology class.
- The Regents of the University of California 1,387 in class
- Novartis AG 1,071 in class
- Merck Sharp & Dohme LLC 889 in class
- Bristol-Myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board of Regents of the University of Texas System 744 in class
- Hoffmann-La Roche Inc. 722 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 721 in class
Assignees with similar portfolio profiles
Two PlainPatent-derived peer sets for Abb, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Abb ranks #28 of 6,058 assignees by patent count in that subclass.
Similar innovation score
Nearest assignees by Innovation Score (63 here).
Similar claim depth
Nearest assignees by average claims per patent (17.7 here).
Abb's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
63 Top 2% higher than 98% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 150 | 24.8% |
| 2016 | 120 | 19.9% |
| 2017 | 82 | 13.6% |
| 2018 | 75 | 12.4% |
| 2019 | 41 | 6.8% |
| 2020 | 34 | 5.6% |
| 2021 | 18 | 3.0% |
| 2022 | 21 | 3.5% |
| 2023 | 30 | 5.0% |
| 2024 | 25 | 4.1% |
| 2025partial year | 8 | 1.3% |
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Abb Vie Inc.'s patent record in context - here's where to go next.
- Abb Vie Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 64.7% of its portfolio - see every assignee active in that class. Explore A61P
- Ranked #759 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Abb Vie Inc. against Essilor International, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 63.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.